Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 436 publications
Agalsidase-A for Fabry's Disease Can be Made Responsible for Hypotension Only After Sufficient Exclusion of Alternative Causes.
Journal: Internal medicine (Tokyo, Japan)
Published: November 19, 2025
Long-term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey.
Journal: European journal of clinical investigation
Published: June 26, 2025
Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.
Journal: Journal of clinical medicine
Published: May 23, 2025
Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis.
Journal: Clinical kidney journal
Published: April 24, 2025
Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease.
Journal: Molecular genetics & genomic medicine
Published: April 14, 2025
Progress and Challenges in the Treatment of Fabry Disease.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 09, 2025
Correction to "Clinical Outcomes in Patients Switching From Agalsidase Beta to Migalastat: A Fabry Registry Analysis".
Journal: Journal of inherited metabolic disease
Published: March 25, 2025
Unexpected Hypotension in a Female Patient with Fabry Disease: Switching from Agalsidase α to β after Long-term ERT.
Journal: Internal medicine (Tokyo, Japan)
Published: February 09, 2025
Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.
Journal: Molecular genetics and metabolism reports
Published: January 22, 2025
A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease.
Journal: Orphanet journal of rare diseases
Published: January 15, 2025
Current treatment status of fabry disease in South Korea: a longitudinal National health insurance service data-based study.
Journal: Orphanet journal of rare diseases
Published: January 07, 2025
Last Updated: 02/24/2026